Development Candidate Triggers Milestone Payment from GlaxoSmithKline
MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified an orally bioavailable small molecule antagonist of the C5a receptor, CCX168, as a candidate for clinical development. The acceptance of the molecule as a development candidate triggered a $5.0 million milestone payment from the alliance with GlaxoSmithKline (NYSE: GSK). CCX168 is designed to specifically target the C5a receptor, a potent inflammatory mediator and component of the complement system, which is associated with the onset of autoimmune diseases such as lupus and certain types of vasculitis, among other diseases.
"In the quest to develop medicinally relevant inhibitor compounds, C5a receptor has been a target of epic difficulty in the pharmaceutical industry. CCX168 is a highly potent and specific C5a receptor small molecule antagonist, and unlike other compounds that have been developed to date. It adds another promising approach to addressing inflammatory and autoimmune diseases to ChemoCentryx's pharmaceuticals portfolio," said Thomas J. Schall, Ph.D., President and Chief Executive Officer. "I am gratified that the ChemoCentryx team has again demonstrated the broad capability of our proprietary technologies and our efficiency in developing a molecule with such excellent properties."
The complement system comprises a set of proteins that regulate certain types of inflammatory responses by the immune system. Fragments of these proteins, such as chemoattractant complement fragment C5a, work to recruit immune system cells including neutrophils and lymphocytes to the site of inflammation. The C5a receptor is highly expressed on innate immune cells, making it an attractive target for small molec
|SOURCE ChemoCentryx, Inc.|
Copyright©2009 PR Newswire.
All rights reserved